FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136016043> ?p ?o ?g. }

• W3136016043 endingPage "28" @default.
• W3136016043 startingPage "19" @default.
• W3136016043 abstract "The optimal management of oligometastatic prostate cancer (PCa) is still debated.The purpose of the present systematic review and meta-analysis is to collect the available evidence to date to better define the role of stereotactic body radiotherapy (SBRT) in selected patients with oligorecurrent PCa.Study methodology complied with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). All prospective studies including PCa patients with nodal and/or bone oligometastases (one to five lesions) were considered eligible. Heterogeneity between study-specific estimates was tested using chi-square statistics and measured with the I2 index. A pooled estimate was obtained by fitting both fixed-effect and DerSimonian and Laird random-effect model.Overall, six works (two randomized and the remainder observational) published between 2013 and 2020 were considered eligible. Globally, data from 445 patients were incorporated, of whom 396 were treated with SBRT (329 in observational studies and the remaining 67 in randomized ones). Regarding local progression-free survival (PFS), five studies reported values close to 100%, while one reported a value of 80% in the observation arm. The benefit in terms of biochemical PFS brought by SBRT was evident in all considered studies. Such a difference in cumulative probabilities between the intervention arm and the comparator arm is maintained even 24 mo after the baseline. All studies but one considered toxicity among the endpoints of interest. Most events were classified as either G1 or G2, and the only G ≥ 3 adverse event was reported in one trial.SBRT is highly cost effective, safe, and with an almost inexistent toxicity risk that makes it the perfect candidate for the optimal management of PCa oligometastatic patients. However, more solid data and a higher level of evidence are needed to affirm its role in the management of these patients.In this work, we reviewed available evidence on the use of stereotactic body radiotherapy in treating oligometastatic prostate cancer patients. We found good evidence that radiotherapy brings important benefits in overall treatment efficacy without major side effects." @default.
• W3136016043 created "2021-03-29" @default.
• W3136016043 creator A5001551311 @default.
• W3136016043 creator A5001805404 @default.
• W3136016043 creator A5008162960 @default.
• W3136016043 creator A5010603967 @default.
• W3136016043 creator A5018040603 @default.
• W3136016043 creator A5018977348 @default.
• W3136016043 creator A5028807129 @default.
• W3136016043 creator A5031481733 @default.
• W3136016043 creator A5036940898 @default.
• W3136016043 creator A5043929475 @default.
• W3136016043 creator A5044720061 @default.
• W3136016043 creator A5053972376 @default.
• W3136016043 creator A5054413808 @default.
• W3136016043 creator A5068250967 @default.
• W3136016043 creator A5071970248 @default.
• W3136016043 creator A5078265351 @default.
• W3136016043 creator A5085426756 @default.
• W3136016043 creator A5085524087 @default.
• W3136016043 date "2021-05-01" @default.
• W3136016043 modified "2023-09-26" @default.
• W3136016043 title "Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies" @default.
• W3136016043 cites W1900676315 @default.
• W3136016043 cites W2107328434 @default.
• W3136016043 cites W2125435699 @default.
• W3136016043 cites W2148199505 @default.
• W3136016043 cites W2156098321 @default.
• W3136016043 cites W2315123323 @default.
• W3136016043 cites W246286872 @default.
• W3136016043 cites W2664930764 @default.
• W3136016043 cites W2766371188 @default.
• W3136016043 cites W2775321189 @default.
• W3136016043 cites W2783057263 @default.
• W3136016043 cites W2787804990 @default.
• W3136016043 cites W2805432229 @default.
• W3136016043 cites W2811260982 @default.
• W3136016043 cites W2897193214 @default.
• W3136016043 cites W2897236707 @default.
• W3136016043 cites W2904508904 @default.
• W3136016043 cites W2919810454 @default.
• W3136016043 cites W2950723941 @default.
• W3136016043 cites W2964111579 @default.
• W3136016043 cites W2972653479 @default.
• W3136016043 cites W2973003210 @default.
• W3136016043 cites W2993652391 @default.
• W3136016043 cites W3000715936 @default.
• W3136016043 cites W3011518560 @default.
• W3136016043 cites W3013251573 @default.
• W3136016043 cites W3024645857 @default.
• W3136016043 cites W3034765338 @default.
• W3136016043 cites W3080549779 @default.
• W3136016043 cites W3092387894 @default.
• W3136016043 cites W3096130167 @default.
• W3136016043 cites W3102188505 @default.
• W3136016043 cites W4294215472 @default.
• W3136016043 doi "https://doi.org/10.1016/j.euros.2021.02.008" @default.
• W3136016043 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8317806" @default.
• W3136016043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34337513" @default.
• W3136016043 hasPublicationYear "2021" @default.
• W3136016043 type Work @default.
• W3136016043 sameAs 3136016043 @default.
• W3136016043 citedByCount "11" @default.
• W3136016043 countsByYear W31360160432021 @default.
• W3136016043 countsByYear W31360160432022 @default.
• W3136016043 countsByYear W31360160432023 @default.
• W3136016043 crossrefType "journal-article" @default.
• W3136016043 hasAuthorship W3136016043A5001551311 @default.
• W3136016043 hasAuthorship W3136016043A5001805404 @default.
• W3136016043 hasAuthorship W3136016043A5008162960 @default.
• W3136016043 hasAuthorship W3136016043A5010603967 @default.
• W3136016043 hasAuthorship W3136016043A5018040603 @default.
• W3136016043 hasAuthorship W3136016043A5018977348 @default.
• W3136016043 hasAuthorship W3136016043A5028807129 @default.
• W3136016043 hasAuthorship W3136016043A5031481733 @default.
• W3136016043 hasAuthorship W3136016043A5036940898 @default.
• W3136016043 hasAuthorship W3136016043A5043929475 @default.
• W3136016043 hasAuthorship W3136016043A5044720061 @default.
• W3136016043 hasAuthorship W3136016043A5053972376 @default.
• W3136016043 hasAuthorship W3136016043A5054413808 @default.
• W3136016043 hasAuthorship W3136016043A5068250967 @default.
• W3136016043 hasAuthorship W3136016043A5071970248 @default.
• W3136016043 hasAuthorship W3136016043A5078265351 @default.
• W3136016043 hasAuthorship W3136016043A5085426756 @default.
• W3136016043 hasAuthorship W3136016043A5085524087 @default.
• W3136016043 hasBestOaLocation W31360160431 @default.
• W3136016043 hasConcept C121608353 @default.
• W3136016043 hasConcept C126322002 @default.
• W3136016043 hasConcept C143998085 @default.
• W3136016043 hasConcept C168563851 @default.
• W3136016043 hasConcept C17744445 @default.
• W3136016043 hasConcept C189708586 @default.
• W3136016043 hasConcept C19527891 @default.
• W3136016043 hasConcept C197934379 @default.
• W3136016043 hasConcept C199539241 @default.
• W3136016043 hasConcept C23131810 @default.
• W3136016043 hasConcept C2779473830 @default.
• W3136016043 hasConcept C2780192828 @default.

• next